This invention relates to combinations of atomoxetine, and a 5HT1.sub.A receptor agonists, kits containing such combinations, pharmaceutical compositions comprising such combinations, and methods of using such combinations to treat patients suffering from ADHD, related disorders, and other central nervous system diseases or disorders.